Resona Health is conducting an at-home 30 – day clinical trial to test the effects of Resonance Frequency Therapy™ (RFT) for relief from PTSD and Trauma. The company is looking for 100 volunteers to participate in the study.
There are no chemicals or drugs involved in this study.
The device is called Pulsar XO and it is an ultra-low energy magnetic field generator. It is safe and effective. The technology is not new, it is over 100 years old.
To date, these therapies have been conducted in clinical settings with expensive equipment – as much as $10,000 + per system. Doctor visits are time-consuming and expensive. A low-cost consumer device has now been developed to demonstrate similar results that can be achieved with this home system. We are looking for 100 volunteers to join us in this study.
Frequency therapies have been around for decades with many successful outcomes. They are safe and effective with little or no known side effects. There are many references and publications on Resona. Health-related to this technology. You can also download the free eBook “Resonance Frequency Therapy for PTSD” to learn more about the technology.
What is required to participate? Research candidates must be committed. This is a small choice considering the potential benefit. Resona seeks individuals that are willing to make the commitment to themselves and will promise to complete the study.
Candidates are required to watch the 10-min orientation video prior to enrollment. Participants will receive a device via mail at no cost. Participants are asked to use the device 3-4 times a week for 30 -days. The device is placed in a shirt pocket or worn around the neck with a lanyard while cooking, cleaning. watching TV, sitting at your computer, reading, or walking.
Participants will fill out a 10 min survey at the beginning and end of the study. There is no cost to participate, and you are free to keep the device at the conclusion of the study. No names will be used in the study.
Volunteers interested in participating should visit Resona.News/future
Questions about this study should be directed to [email protected].